Cytokine release in an ovarian carcinoma patient following intravenous administration of bispecific antibody OC/TR F(ab')2.
J G
JG
Tibben
O C
OC
Boerman
R A
RA
Claessens
F H
FH
Corstens
M
M
van Deuren
P H
PH
de Mulder
J W
JW
van der Meer
K G
KG
Keijser
L F
LF
Massuger
D000368:Aged; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use*; D015295:Antigens, Tumor-Associated, Carbohydrate; D017252:CD3 Complex / Q000276:immunology; D016207:Cytokines / Q000378:metabolism*; D005260:Female; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000276:immunology* / Q000627:therapeutic use; D007371:Interferon-gamma / Q000097:blood; D008213:Lymphocyte Activation; D016853:Muromonab-CD3 / Q000276:immunology; D010051:Ovarian Neoplasms / Q000276:immunology* / Q000378:metabolism / Q000628:therapy; D013601:T-Lymphocytes / Q000276:immunology*; D014409:Tumor Necrosis Factor-alpha / Q000032:analysis
D000911:Antibodies, Monoclonal; D015295:Antigens, Tumor-Associated, Carbohydrate; D017252:CD3 Complex; D016207:Cytokines; D007140:Immunoglobulin Fab Fragments; D016853:Muromonab-CD3; D014409:Tumor Necrosis Factor-alpha; D007371:Interferon-gamma